A Phase 2 interventional study of Anastrozole 1 mg and Anastrozole 5 mg in Anovulation, sponsored by EMD Serono. Completed at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-07-17.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing clomiphene in Anovulation — none open to participants now, 1 under way, 1 of them phase 3. Clomiphene · Anovulation.
Among the 15 studies testing clomiphene in Anovulation, this one is the 3rd largest by enrollment, is the only one that started in 2005, is one of 2 in phase 2, and was the 1st registered.
76 studies on the registry are indexed under Anovulation; 7 are open to participants now.
Browse Anovulation studies →None of the 15 studies testing clomiphene in Anovulation is open now. The open studies under Anovulation, anywhere →
Clomiphene: first FDA approval 1967 (CLOMID). What it is approved for, and how studies give it, is on its page →
Of the 5 Anovulation studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 271 is above the median of 80 across 53 interventional studies indexed under Anovulation.
Median enrollment 159 across the 15 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 2 studies filed under Anovulation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing clomiphene in Anovulation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Clomiphene Citrate 50 mg
Drug: Clomiphene Citrate 100 mg
Drug: Anastrozole 1 mg
Drug: Anastrozole 5 mg
Drug: Anastrozole 10 mg
Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
Ovulation Rate in Cycle 1
Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron \[P4\] level greater than or equal to \[\>=\] 10 nanogram per milliliter \[ng/mL\] and/or pregnancy).
Time frame: Up to 1 month
Number of Subjects With Clinical Pregnancy in Cycle 1
Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.
Time frame: Up to 1 month
| Milestone | Clomiphene Citrate 50 Milligram (mg) | Clomiphene Citrate 100 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg |
|---|---|---|---|---|---|
| Started | 77 | 0 | 79 | 76 | 39 |
| Completed | 53 | 0 | 60 | 58 | 17 |
| Not completed | 24 | 0 | 19 | 18 | 22 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 8 | 5 | 8 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 3 | 0 | 2 | 2 | 7 |
| Withdrew: Pregnancy unrelated to therapy | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Non resolving cyst > 25mm | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Discontinued before start of cycle 2 | 15 | 0 | 5 | 8 | 5 |
| Milestone | Clomiphene Citrate 50 Milligram (mg) | Clomiphene Citrate 100 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg |
|---|---|---|---|---|---|
| Started | 43 | 10 | 42 | 52 | 41 |
| Completed | 29 | 4 | 28 | 33 | 11 |
| Not completed | 14 | 6 | 14 | 19 | 30 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 2 | 1 |
| Withdrew: Lack of efficacy | 1 | 3 | 7 | 6 | 16 |
| Withdrew: Other | 2 | 1 | 2 | 8 | 7 |
| Withdrew: Pregnancy unrelated to therapy | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Non resolving cyst > 25mm | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Discontinued before start of cycle 3 | 10 | 1 | 3 | 3 | 6 |
| Milestone | Clomiphene Citrate 50 Milligram (mg) | Clomiphene Citrate 100 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg |
|---|---|---|---|---|---|
| Started | 23 | 10 | 26 | 24 | 22 |
| Completed | 23 | 8 | 25 | 23 | 21 |
| Not completed | 0 | 2 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 1 | 0 |
Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron \[P4\] level greater than or equal to \[\>=\] 10 nanogram per milliliter \[ng/mL\] and/or pregnancy).
| percentage of subjects | Clomiphene Citrate 50 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg |
|---|---|---|---|---|
| Ovulation Rate in Cycle 1 | 64.9 | 30.4 | 36.8 | 35.9 |
Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity.
| subjects | Clomiphene Citrate 50 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg |
|---|---|---|---|---|
| Number of Subjects With Clinical Pregnancy in Cycle 1 | 10 | 4 | 7 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clomiphene Citrate 50 mg (Cycle 1) | — | 1/77 (1.3%) | 23/77 (29.9%) |
| Anastrozole 1 mg (Cycle 1) | — | 0/79 (0%) | 12/79 (15.2%) |
| Anastrozole 5 mg (Cycle 1) | — | 0/76 (0%) | 17/76 (22.4%) |
| Anastrozole 10 mg (Cycle 1) | — | 0/39 (0%) | 4/39 (10.3%) |
| Clomiphene Citrate 50 mg (Cycle 2) | — | 0/43 (0%) | 6/43 (14%) |
| Clomiphene Citrate 100 mg (Cycle 2) | — | 0/10 (0%) | 2/10 (20%) |
| Anastrozole 1 mg (Cycle 2) | — | 0/42 (0%) | 2/42 (4.8%) |
| Anastrozole 5 mg (Cycle 2) | — | 0/52 (0%) | 4/52 (7.7%) |
| Anastrozole 10 mg (Cycle 2) | — | 0/41 (0%) | 7/41 (17.1%) |
| Clomiphene Citrate 50 mg (Cycle 3) | — | 0/23 (0%) | 4/23 (17.4%) |
| Clomiphene Citrate 100 mg (Cycle 3) | — | 0/10 (0%) | 2/10 (20%) |
| Anastrozole 1 mg (Cycle 3) | — | 0/26 (0%) | 1/26 (3.8%) |
| Anastrozole 5 mg (Cycle 3) | — | 0/24 (0%) | 2/24 (8.3%) |
| Anastrozole 10 mg (Cycle 3) | — | 0/22 (0%) | 2/22 (9.1%) |
| Event | Clomiphene Citrate 50 mg (Cycle 1) | Anastrozole 1 mg (Cycle 1) | Anastrozole 5 mg (Cycle 1) | Anastrozole 10 mg (Cycle 1) | Clomiphene Citrate 50 mg (Cycle 2) | Clomiphene Citrate 100 mg (Cycle 2) | Anastrozole 1 mg (Cycle 2) | Anastrozole 5 mg (Cycle 2) | Anastrozole 10 mg (Cycle 2) | Clomiphene Citrate 50 mg (Cycle 3) | Clomiphene Citrate 100 mg (Cycle 3) | Anastrozole 1 mg (Cycle 3) | Anastrozole 5 mg (Cycle 3) | Anastrozole 10 mg (Cycle 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/77 | 0/79 | 0/76 | 0/39 | 0/43 | 0/10 | 0/42 | 0/52 | 0/41 | 0/23 | 0/10 | 0/26 | 0/24 | 0/22 |
| Event | Clomiphene Citrate 50 mg (Cycle 1) | Anastrozole 1 mg (Cycle 1) | Anastrozole 5 mg (Cycle 1) | Anastrozole 10 mg (Cycle 1) | Clomiphene Citrate 50 mg (Cycle 2) | Clomiphene Citrate 100 mg (Cycle 2) | Anastrozole 1 mg (Cycle 2) | Anastrozole 5 mg (Cycle 2) | Anastrozole 10 mg (Cycle 2) | Clomiphene Citrate 50 mg (Cycle 3) | Clomiphene Citrate 100 mg (Cycle 3) | Anastrozole 1 mg (Cycle 3) | Anastrozole 5 mg (Cycle 3) | Anastrozole 10 mg (Cycle 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/77 | 5/79 | 9/76 | 2/39 | 0/43 | 0/10 | 1/42 | 1/52 | 3/41 | 2/23 | 0/10 | 1/26 | 1/24 | 2/22 |
| Adnexa uteri painReproductive system and breast disorders | 6/77 | 2/79 | 4/76 | 0/39 | 2/43 | 1/10 | 0/42 | 0/52 | 1/41 | 2/23 | 0/10 | 0/26 | 0/24 | 0/22 |
| Hot flushVascular disorders | 0/77 | 0/79 | 0/76 | 0/39 | 3/43 | 1/10 | 0/42 | 2/52 | 0/41 | 0/23 | 1/10 | 0/26 | 1/24 | 0/22 |
| Breast tendernessReproductive system and breast disorders | 0/77 | 0/79 | 0/76 | 0/39 | 0/43 | 0/10 | 0/42 | 0/52 | 0/41 | 0/23 | 1/10 | 0/26 | 0/24 | 0/22 |
| NauseaGastrointestinal disorders | 4/77 | 5/79 | 2/76 | 2/39 | 1/43 | 0/10 | 1/42 | 1/52 | 3/41 | 0/23 | 0/10 | 0/26 | 0/24 | 0/22 |
| Back painMusculoskeletal and connective tissue disorders | 4/77 | 0/79 | 2/76 | 0/39 | 0/43 | 0/10 | 0/42 | 0/52 | 0/41 | 0/23 | 0/10 | 0/26 | 0/24 | 0/22 |
| Age, Continuous(years) | Clomiphene Citrate 50 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg | Total |
|---|---|---|---|---|---|
| Mean | 29.0 ± 3.9 | 28.8 ± 3.9 | 29.6 ± 3.9 | 29.3 ± 3.4 | 29.2 ± 3.8 |
| Sex: Female, Male(Participants) | Clomiphene Citrate 50 mg | Anastrozole 1 mg | Anastrozole 5 mg | Anastrozole 10 mg | Total |
|---|---|---|---|---|---|
| Female | 77 | 79 | 76 | 39 | 271 |
| Male | 0 | 0 | 0 | 0 | 0 |
Ran from Mar 2005 to primary completion in Dec 2007, 33 months.
Results were first posted in Jul 2018, 10 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Anastrozole · Clomiphene